Art Biktarvy denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues a "Not FDA-Approved" Denial for Biktarvy — and Why It Is Appealable

A denial stating that Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) is not FDA-approved for the requested indication is factually contestable. Biktarvy carries full FDA approval for HIV-1 treatment in adults and certain pediatric populations. This denial most commonly arises from one of three scenarios: (1) a coding or claims-entry error where the submitted diagnosis code does not match the drug's approved indication; (2) a plan policy that uses an outdated drug database entry; or (3) a request for use in a specific population (such as a particular pediatric age or weight range) that requires precise documentation matching the FDA label's approved population.

Because this denial type rests on a verifiable factual question — whether FDA approval exists — it is straightforward to address with documentation.

## The Federal Appeal Framework

• ACA §2719 External Review: Independent external review is available after internal appeal. Check your denial letter for the exact filing deadline.
• ERISA §503 (employer-sponsored plans): Full-and-fair review with written explanation of plan provisions used.
• Expedited review: Available if the standard timeline would seriously jeopardize health. Especially relevant for HIV therapy where treatment interruption carries clinical risk.

## What to Gather

1. FDA label for Biktarvy — the complete FDA-approved prescribing information is publicly available. Print and attach it, highlighting the approved indications and the patient populations covered. 2. Diagnosis documentation — chart records confirming HIV-1 infection diagnosis with the specific ICD-10 code that matches the FDA-approved indication. 3. Patient population documentation — if the denial relates to a specific patient characteristic (age, weight, renal status), include chart documentation confirming the patient falls within the FDA-approved population as stated in the prescribing label. 4. Prescriber letter — attests that the prescribed indication matches the FDA-approved label and explains the clinical basis for the prescription. 5. BCBS's not-FDA-approved policy — obtain the plan's published criteria and show directly that none of the criteria apply to this drug and indication.

## Criteria-Mapping Structure

| BCBS "Not FDA-Approved" Criterion | Why It Does Not Apply to This Claim | |---|---| | [Paste each criterion from plan policy] | [Cite FDA label approval date, indication text, and matching diagnosis documentation] |

## Next Steps

Attach the FDA label to your written internal appeal and request correction of any coding error through the plan's provider services line simultaneously. If the plan's reviewer upholds the denial despite the FDA label, escalate to external review — independent reviewers apply a factual standard and will review the label directly.